PharmaCielo Ltd.
TSXV:PCLO Rapporto sulle azioni
Cap. di mercato: CA$15.3m
PharmaCielo Dividendi e riacquisti
Dividendo criteri di controllo 0/6 PharmaCielo non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-2.8%
Rendimento del riacquisto
Rendimento totale per gli azionisti -2.8% Rendimento futuro dei dividendi n/a Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Mostra tutti gli aggiornamenti
New major risk - Market cap size Nov 07
Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023) Aug 18 PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 11
PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 10
PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024 Dec 28
Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022) Dec 01 PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding Oct 07
Is PharmaCielo (CVE:PCLO) Using Too Much Debt? Oct 04
New major risk - Financial position Aug 31
Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022) Aug 31 Pharmacielo Ltd. Appoints Marc Lustig as CEO PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding
CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock. Jun 15
New minor risk - Share price stability Jun 08
First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022) Jun 03
Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021) May 03
Is PharmaCielo (CVE:PCLO) Using Too Much Debt? Feb 25
Independent Lead Director recently bought CA$83k worth of stock Dec 02
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021) Oct 29
Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021) Aug 30
PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt Aug 03
Less than half of directors are independent Aug 01
PharmaCielo Ltd. Announces Board and Executive Changes Jul 29
CEO, President & Chairman of the Board recently bought CA$67k worth of stock Jul 17
PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022 Jul 01
CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock. Jun 25
First quarter 2022 earnings: EPS and revenues miss analyst expectations Jun 01
High number of new directors May 31
Full year 2021 earnings: Revenues miss analyst expectations May 01
High number of new directors Apr 27
Independent Lead Director recently bought CA$92k worth of stock Mar 30
Independent Lead Director recently bought CA$292k worth of stock Mar 16
PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding Dec 23
Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load? Dec 23
Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 28
Independent Lead Director recently bought CA$1.8m worth of stock Sep 09
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
CEO, President & Director Henning von Koss has left the company Aug 24
Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021 Aug 22
Second quarter 2021 earnings released Aug 21
Independent Chairman of the Board Simon Langelier has left the company Jun 12
Chief Financial Officer Scott Laitinen has left the company Jun 04
First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020) Jun 02
Is PharmaCielo (CVE:PCLO) A Risky Investment? May 14
Independent Director recently bought CA$115k worth of stock Apr 10
Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019) Apr 09
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate Feb 19
Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit? Feb 16
New 90-day high: CA$2.68 Feb 11
PharmaCielo Provides Update on GMP Compliance Process Feb 03
PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity Dec 20
CEO, President & Director recently sold CA$88k worth of stock Dec 19
New 90-day high: CA$2.18 Dec 17
PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc Dec 13
Revenue and earnings miss expectations Dec 02 Pharmacielo Ltd. Announces Step Down of David Attard as Board Member, Effective December 1, 2020
PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate Nov 19
New 90-day high: CA$0.74 Nov 19
PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars Nov 07
PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding Nov 04
PharmaCielo Ltd. Appoints Marc Lustig as Lead Director Nov 03
PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand Sep 22
New 90-day low: CA$0.54 Sep 18
New 90-day low - CA$0.55 Aug 06
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di PCLO siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di PCLO siano aumentati.
Rendimento dei dividendi rispetto al mercato PharmaCielo Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di PCLO rispetto al mercato? Segmento Rendimento dei dividendi Azienda (PCLO) n/a Fondo del 25% del mercato (CA) 1.8% Top 25% del mercato (CA) 6.1% Media del settore (Pharmaceuticals) 2.3% Analista previsionale (PCLO) (fino a 3 anni) n/a
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di PCLO rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di PCLO rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di PCLO per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché PCLO non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
